Clinical Trial Update: A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ASP8232 as add-on therapy to ACE inhibitors or ARBs to reduce albuminuria in patients with type 2 diabetes and chronic kidney disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• ASP8232 (ASP8232)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Status: COMPLETED